IMMUNOAFFINITY PURIFICATION WITH ANTI-ID ANTIBODIES

放射免疫闪烁成像的主要局限性之一是 临床上检测肿瘤的技术一直是实现 肿瘤与正常组织结合放射性比率较高。 部分 困难来自于这样的事实，即相当大比例的单克隆 抗体（MoAb）在放射性标记过程中失活， 单克隆抗体，当静脉注射时，非特异性定位在正常 组织中 该建议通过制定一项 创新的，新的方法，有效地分离抗体损坏， 放射性标记程序从保留其原始亲和力的那些中分离， 的特异性 初步研究表明，抗独特型（抗Id） 可以制备识别抗黑色素瘤单抗结合位点的单抗， 作为亲和基质，以在放射性标记后纯化抗黑素瘤单克隆抗体 程序. 在这项研究中，免疫反应性，特异性，亲和力和 将测定In-111标记的抗黑色素瘤单克隆抗体的肿瘤组织比 在免疫亲和性有效之前和之后， 提高放射免疫显像检测肿瘤的灵敏度。 因此，我们相信，实验室之间存在现成的商业市场。 进行临床或实验放射免疫闪烁技术， 含有抗肿瘤单克隆抗体的试剂盒，可用于放射性标记并预先包装 抗Id单克隆抗体亲和柱，用于在单克隆抗体已经 标签。

One of the primary limitations in the use of radioimmunoscintigraphic techniques to detect tumors clinically has been the difficulty in achieving high tumor to normal tissue ratios of bound radioactivity. Part of this difficulty arises from the fact that a significant proportion of monoclonal antibodies (MoAb) are inactivated during radiolabeling procedures and such MoAb, when injected intravenously, localize non-specifically in normal tissues. This proposal addresses the problem through the development of an innovative, new method for effectively separating antibodies damaged during radiolabeling procedures from those retaining their original affinity and specificity. Preliminary studies indicate that anti-idiotypic (anti-Id) MoAb recognizing the combining sites of anti-melanoma MoAb can be prepared as affinity matrices to purify the anti-melanoma MoAb after radiolabeling procedures. In this study the immunoreactivity, specificity, affinity and tumor to tissue ratios of In-111-labeled anti-melanoma MoAb will be assayed before and after immunoaffinity is effective, it may be possible to increase the sensitivity of tumor detection by radioimmunoscintigraphy. Therefore we believe a ready commercial market exists among laboratories performing clinical or experimental radioimmunoscintigraphy techniques for kits containing anti-tumor MoAb ready for radiolabeling and prepackaged anti-Id MoAb affinity columns for purification after the MoAb have been labeled.